Physician profile
Brian L Schmidt
NPI 1063577781
$3,208.77
in general payments reported to CMS, 2019-2025
28 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57.31 · 2023: $861 · 2024: $1,298 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $435.82 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $385.74 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $325.46 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $275.85 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $256.92 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $230.13 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $201.03 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $184.63 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $129.97 | 2023-2025 | |
| Amgen INC. | $111.62 | 2024-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.95 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.40 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $66.75 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $51.48 | 2024-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $46.40 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $45.21 | 2024 | |
| Seqirus USA INC | $36.78 | 2024-2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $34.27 | 2024 | Voquezna |
| Mylan Specialty L.P. | $34.08 | 2022-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $30.11 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $28.39 | 2023-2024 | Contrave |
| Kowa Pharmaceuticals America, INC. | $28.21 | 2023-2024 | Livalo |
| Dexcom, INC. | $25.00 | 2023 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $20.99 | 2025 | Opsumit, Uptravi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.57 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $20.28 | 2024 | Camzyos |
| Bioventus LLC | $17.14 | 2025 | Durolane |
| Janssen Pharmaceuticals, INC | $14.59 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.